15102KAA8
Celcuity Inc.
Could not find a ticker for this position, may be a filing error
A clinical-stage biotech developing gedatolisib, a drug aimed at blocking cancer-driving cell signals to treat advanced breast and prostate cancer. Founded in 2012 by Brian Sullivan and Lance Laing, the company first built CELsignia, a tool that reads living tumor cells, before pivoting to drug development. Its name blends "cell" and "acuity" — a nod to the sharp, precise view the founders wanted of a tumor's inner workings.
CONVERTIBLEUnderlying: CELCCUSIP: 15102KAA8HealthcareUS1 derivative reporter
Celcuity Inc 2.75% Convertible Bond due 2031
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
